Cetuximab plus 5‐fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15695 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Julia Huynh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbol…. Hauptthemen laut MEDLINE: Cetuximab, Fluorouracil, Skin Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
For patients with locally advanced (la) or metastatic (m) cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery/radiation or systemic anti‐PD1 therapy, anti‐EGFR in combination with chemotherapy is a rational treatment option. Patients and Methods We analyzed data from 20 patients with cSCC in this monocentric, retrospective study. 4/20 patients had laSCC and 16/20 patients had mSCC. Patients received combined cetuximab and 5‐FU between 2015 and 2023. Nine patients received cetuximab + 5‐FU as second‐line therapy (8 patients after anti‐PD‐1, 1 patient after radiochemotherapy).
Results
One patient had partial response (PR) and 9/20 (45.0%) had stable disease (SD). Disease control rate (PR + SD) was 50%. No complete remissions were observed. One of the non‐responders suffered from laSCC, nine patients had mSCC with distant metastases (including parotid) and locoregional lymph node metastases. Treatment was well tolerated, with a median PFS of 3 months (95% confidence interval [CI] 2 months to not assessable [NA]) and median overall survival (OS) of 29 months (95% CI 11–NA). The most common adverse event was acne‐like rash in 40.0% of patients.
Conclusions
For patients with advanced cSCC who are contraindicated to or have progressed on first‐line cemiplimab, combination of cetuximab and 5‐FU is a well‐tolerated but limited treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Julia Huynh, Rose K C Moritz, Gabor Dobos
Zitieren
APA
Huynh, J., Eigentler, T., Moritz, R. K. C., Poch, G., Schlaak, M., & Dobos, G. (2025). Cetuximab plus 5‐fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15695
Vancouver
Huynh J, Eigentler T, Moritz RKC, Poch G, Schlaak M, Dobos G. Cetuximab plus 5‐fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15695
BibTeX
@article{Huynh2025,
author = {Huynh, Julia and Eigentler, Thomas and Moritz, Rose K C and Poch, Gabriela and Schlaak, Max and Dobos, Gabor},
title = {Cetuximab plus 5‐fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15695}
}
EUVIMED